Harnessing the immune system to achieve deep and durable clinical responses in cancer

Leveraging our proprietary platform, Xilio is advancing a deep pipeline of novel clinical and preclinical immunotherapies designed to achieve tumor-selective activation.

Metastatic Microsatellite Stable Colorectal Cancer

Vilastobart

In combination with atezolizumab, masked anti-CTLA-4+PD-L1

Advanced Solid Tumors

XTX301

Masked IL-12

Advanced Solid Tumors 2

XTX501

Masked PD-1/IL-2

Prostate

PSMA

Masked T Cell Engager

Gastric, Pancreatic, Esophageal, Lung

CLDN18.2

Masked T Cell Engager

Prostate, Lung, Colorectal

STEAP1

Masked T Cell Engager